A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Inclusion Criteria: * Male or female subjects ≥18 years old or other legal maturity age according to the country of residence * Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following: * Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization and/or * Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months. * Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava \[IVC\] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE * Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated * Able to provide written informed consent Exclusion Criteria: * Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE * More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants * An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to …